CRBU
Caribou Biosciences, Inc.1.6900
-0.0200-1.17%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
157.96MP/E (TTM)
-Basic EPS (TTM)
-1.70Dividend Yield
0%Recent Filings
10-K
FY2025 results
Caribou Biosciences posted a $148.1M net loss for FY2025 ended December 31, 2025, nearly flat from $149.1M in 2024 amid pipeline prioritization that axed preclinical work and cut headcount 32% to 97 employees. Cash reserves stood at $142.8M, funding operations through at least 12 months but falling short for the planned vispa-cel pivotal trial without fresh capital. ANTLER phase 1 data shone in Q4 with 82% ORR and 64% CR in 22 2L LBCL patients via partial HLA-matched vispa-cel; CaMMouflage showed 92% ORR in BCMA-naïve r/r MM at RDE. No quarterly financials disclosed. Pipeline narrowed to vispa-cel and CB-011 risks trial delays from funding gaps.
8-K
Q4 results, pipeline advances
Caribou Biosciences reported Q4 and full-year 2025 results, with licensing revenue up to $11.2M but cash dropping to $142.8M from $249.4M amid R&D cuts to $109.4M. Vispa-cel phase 1 data matched autologous CAR-T efficacy in 2L LBCL; CB-011 dose expansion advances in r/r MM. Cash funds operations into 2H 2027. Funding hunt begins.
8-K
Strong CAR-T data, $159M cash
Caribou Biosciences unveiled strong Q3 2025 data for allogeneic CAR-T therapies vispa-cel and CB-011, matching autologous efficacy with outpatient-friendly safety. Vispa-cel hit 82% ORR and 64% CR in confirmatory LBCL cohort; CB-011 showed 92% ORR in MM dose escalation. Cash stands at $159.2M, funding operations into 2H 2027. Data propel pivotal trials forward.
10-Q
Q3 FY2025 results
Caribou narrowed Q3 losses to $27.5M from $34.7M y/y, with licensing revenue ticking up 9% to $2.2M while R&D expenses dropped 26% to $22.4M on lower external clinical costs and post-restructuring workforce cuts. Operating loss improved to $29.4M from $38.2M y/y, though YTD net loss widened to $121.6M from $113.6M due to $12.2M asset impairments and $9.2M equity investment write-off, offset by lower opex. Cash burn slowed, with $159.2M in cash and marketable securities at quarter-end funding operations at least 12 more months. Restructuring complete. Nasdaq bid price compliance remains a risk.
8-K
Robust CAR-T phase 1 data released
Caribou Biosciences unveiled strong phase 1 data for allogeneic CAR-T vispa-cel in r/r LBCL, posting 82% ORR and 64% CR in the 22-patient confirmatory cohort with 4+ HLA matching, alongside 51% 12-month PFS. CB-011 in r/r MM hit 92% ORR and 75% CR in 12 BCMA-naïve patients at the 450x10^6 dose. Cash sits at ~$159M; vispa-cel eyes FDA-guided phase 3 in 2L LBCL. Data may evolve.
ALLO
Allogene Therapeutics, Inc.
1.54+0.07
CABA
Cabaletta Bio, Inc.
2.39+0.00
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CLLS
Cellectis S.A.
4.06-0.73
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
MBIO
Mustang Bio, Inc.
1.07-0.06
TCRX
TScan Therapeutics, Inc.
0.95-0.01